RFK Jr. Pushes for the ‘Deprescribing’ of Antidepressants as Experts Say It’s ‘Not Justifiable Medically’

**Robert F. Kennedy Jr. Advocates for Reduced Reliance on Antidepressants Amid Controversy**

Robert F. Kennedy Jr., a prominent figure in health advocacy and the current Secretary of Health and Human Services, has launched initiatives aimed at decreasing the use of antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs). This class of psychiatric medications is prescribed frequently for managing conditions like depression and anxiety, with estimates suggesting that over one in ten adults in the United States were taking them as of 2025.

Speaking at the Mental Health and Overmedicalization Summit on 4 May, Kennedy asserted the need for a shift in how psychiatric medications are perceived within the healthcare community. “Psychiatric medications have a role in care, but we will no longer treat them as the default,” he stated. His comments sought to frame these medications as just one of many treatment options, advocating for “full transparency” about their use and a clearer pathway for discontinuation when they are no longer deemed necessary.

Kennedy’s initiatives, however, have sparked concern among mental health professionals and organisations. Experts caution that restricting access to SSRIs could lead to adverse outcomes for those who depend on them for stability and relief from debilitating symptoms. Dr. J. John Mann from the New York State Psychiatric Institute remarked on this issue, suggesting that such a move is not medically justifiable: “There are a lot of prescriptions because there are a lot of folks with illnesses that can respond to these medications.”

His recent decision has followed the publication of a letter to colleagues in which he encouraged mental health providers to consider alternative treatments. These include social interaction, psychotherapy, physical exercise, and dietary adjustments. “Our goal is straightforward: to reduce unnecessary dependence on medication, to improve patient outcomes and to return control to the patients,” Kennedy explained in his correspondence.

Despite Kennedy’s assurances that individuals currently on psychiatric medications need not feel pressured to cease usage, the focus of his initiatives appears to endorse the “deprescribing” movement. This approach promotes the reduction of prescription rates for SSRIs and similar drugs, which could significantly impact those who rely on these medications for their mental wellbeing.

The Health and Human Services department has articulated its commitment to preventing undue initiation of psychiatric medications while also supporting tapering and discontinuation for patients who are not receiving clinical benefits from their current therapies. Critics, however, express significant unease over this stance, arguing that sudden policy changes could jeopardise public health and patient safety. Dr. Mark Olfson, a psychiatric professor at Columbia University, warned that limiting access to antidepressants might lead to serious health repercussions for individuals who find relief from them.

This sentiment is echoed by the American Foundation for Suicide Prevention (AFSP), which issued a statement highlighting the crucial role antidepressants play in alleviating severe depression and reducing suicidal tendencies. They maintain that extensive research backs the efficacy of these medications during acute depressive phases and in preventing future episodes. “While all medications carry potential risks, decades of research show that the judicious use of antidepressants reduces suicide risk overall,” the AFSP’s statement noted.

Additional voices from the psychiatric community have echoed these concerns. Dr. Theresa Miskimen Rivera, president of the American Psychiatric Association, pointed out that attributing the nation’s mental health crisis solely to the overprescription of psychiatric drugs oversimplifies a complex issue. However, she did emphasize the necessity for better training of healthcare practitioners to ensure safe prescribing practices.

As Kennedy’s initiatives gain traction, the conversation surrounding mental health treatment continues to evolve. While his objectives may aim to empower patients and encourage non-pharmaceutical interventions, the potential ramifications of reducing access to proven antidepressant therapies cannot be overlooked. The balance between effective treatment and patient autonomy remains a persistent challenge in modern mental healthcare, indicating an ongoing debate that promises to shape the future of psychiatric treatment in the United States.